Speakers include: Peter Winter (Managing Director, Editorial, Burrill & Company), Jean-François Pariseau (Director, Business Development Bank of Canada), Patrice Sarrazin (Senior Scientific Evaluator, Health Canada), Terry Allen (The Centre for Drug Research and Development), and Martin Leblanc (President, Caprion Proteomics).
The Consulate General is responsible for Canadian interests in Northern California, Nevada and Hawaii. Our offices are located in San Francisco and Palo Alto. We focus on promoting trade and investment, advancing Canada's interests in the region and providing consular services to Canadians.
Dr. Theresa M. Allen is Division Chair. Drug Delivery, Center for Drug Research and Development (CDRD) at the University of Alberta.
President and CEO Martin LeBlanc, of Caprion Proteomics, led the development and implementation of Caprion's proteomics technology when he co-founded the company. He also helped establish profitable proteomics services by creating multiple revenue-generating biomarker and target identification alliances with over 20 major pharmaceutical companies. In 2007, he led the spin-out, recapitalization, and sale of Caprion Proteomics to Great Point Partners, LLC, and in 2008 concluded Caprion's equity financing and strategic distribution alliance with Covance Inc., a leading global provider of drug development services. Prior to Caprion, LeBlanc worked as a management consultant with McKinsey & Company, as vice-president of sales and marketing (and later as general manager) at Advanced Bioconcept Ltd.
He is a member of the Board of Directors of Victhom Human Bionics (TSX: VHB), Mispro Pharma, Soricimed Pharmaceuticals, and Chairman of the Board of the Atlantic Cancer Research Institute, and he earned his bachelor's degree in economics from the University of Moncton prior to completing a master's in economics and politics at Oxford University as a Rhodes Scholar.
Mr. Jean-Francois Pariseau is a Director of Venture Capital at BDC Venture Capital. He joined the firm in July, 2001 and is based at Montreal office. He has over 15 years of investment and entrepreneurial experience in the life sciences sector. Mr. Pariseau's experience includes transactions in private and in public companies, initial public offerings, merger and acquisitions, and fund investments. Prior to joining BDC, Mr. Pariseau was an Investment Manager with CDP ... Capital Technology Ventures and the Founder Manager of two health care companies specializing in regulatory affairs and pharmaceutical product distribution. He also served as an Investment Manager at a venture capital fund with global investment activities in healthcare, information technology and advanced technologies; his duties included being responsible for healthcare investments in Canada and the United States.
Over the past 12 years, Mr. Pariseau has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Prior to this, he was Chief Executive Officer of a consulting company specializing in regulatory affairs as well as Vice President of Research and Development for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau currently sits on the Board of Directors of AngioChem Inc., Resonant Medical Inc., Osprey Pharmaceuticals USA, and BioQuebec. He was a Director on the Board of Neokimia Inc. Mr. Pariseau holds an M.B.A. from HEC in Montreal, an M.Sc. in Biomedical Sciences from University de Montreal, and a B.Sc. in Biotechnology from University de Sherbrooke.
Patrice Sarrazin is Senior Scientific Evaluator for Health Canada.
Peter Winter oversees the editorial content for the Burrill Media Group and directs Burrill & Company's corporate communications. Mr. Winter has over 25 years experience as a journalist, writer, editor and consultant in the biotechnology and life sciences sectors. He was founder and Editor of Canadian Biotech News a weekly newsletter that has been serving the industry for over 19 years and has become the publication of record for the Canadian biotechnology and life sciences sectors.
Caprion Proteomics president Martin Leblanc heralds the research environment in Canada as very welcoming to businesses in life sciences. Advantages in Canada include easy access to sample groups and the single payer health system.